APTIVUS

LOE Approaching

tipranavir

NDAORALCAPSULEPriority Review
Approved
Jun 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

HIV Protease Inhibitors

Pharmacologic Class:

Protease Inhibitor

Indications (1)

Clinical Trials (5)

NCT01068925Phase 1Completed

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Started Feb 2010
18 enrolled
Infection, Human Immunodeficiency VirusHIV Infections
NCT00976950N/ACompleted

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Started Sep 2009
42 enrolled
HIV Infections
NCT02244190Phase 1Completed

Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers

Started Apr 2008
32 enrolled
Healthy
NCT00530920Phase 2Completed

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Started Oct 2007
85 enrolled
HIV Infections
NCT02251795Phase 1Completed

Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

Started Aug 2007
52 enrolled
Healthy